Biovie (BIVI) Interest & Investment Income (2013 - 2026)
Biovie (BIVI) posted Interest & Investment Income of $121045.0 for Q1 2026, down 39.11% sequentially from $198797.0 in Q4 2025, and down 38.71% YoY from $197494.0 in Q1 2025.
Biovie (BIVI) Interest & Investment Income (2013 - 2026) Analysis & Trends
Biovie has reported Interest & Investment Income for 12 years, with the latest figure at $121045.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 38.71% year-over-year to $121045.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $697811.0 (down 26.28% YoY) and the FY2025 annual result came in at $853029.0, down 24.96% from the prior year.
- Interest & Investment Income slipped to $121045.0 in Q1 2026 per BIVI's latest filing, from $198797.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $462223.0 in Q3 2023 and troughed at $11459.0 in Q2 2022.
- A 5-year average of $182093.9 and a median of $197494.0 in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income jumped 2127.15% in 2023, then plunged 51.63% in 2024.
- Over 5 years, Interest & Investment Income stood at $83269.0 in 2022, then soared by 161.84% to $218029.0 in 2023, then climbed by 16.06% to $253036.0 in 2024, then slipped by 21.44% to $198797.0 in 2025, then plunged by 39.11% to $121045.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $121045.0, $198797.0, and $199027.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 77,902.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77,902.00 |
| Mar 31, 2026 | 121,045.00 |
| Dec 31, 2025 | 198,797.00 |
| Sep 30, 2025 | 199,027.00 |
| Jun 30, 2025 | 178,942.00 |
| Mar 31, 2025 | 197,494.00 |
| Dec 31, 2024 | 253,036.00 |
| Sep 30, 2024 | 223,557.00 |
| Jun 30, 2024 | 272,517.00 |
| Mar 31, 2024 | 183,933.00 |
| Dec 31, 2023 | 218,029.00 |
| Sep 30, 2023 | 462,223.00 |
| Jun 30, 2023 | 255,209.00 |
| Mar 31, 2023 | 182,201.00 |
| Dec 31, 2022 | 83,269.00 |
| Sep 30, 2022 | 41,585.00 |
| Jun 30, 2022 | 11,459.00 |
| Mar 31, 2022 | 13,273.00 |
| Dec 31, 2021 | 11,702.00 |
| Sep 30, 2021 | 7,645.00 |